PAS sways NICE decision

Pharma NICE Update NICE has recommended the use of GSK’s Revolade (eltrombopag) in draft guidance for treating chronic immune (idiopathic) thrombocytopenic purpurai (ITP).

Original guidance, published in October 2010, was reviewed by NICE after GSK agreed a Patient Access Scheme with the DH to supply the treatment at a discounted rate.

The guidance now recommends Revolade in adults who have had their spleen removed and whose condition is refractory to other treatments and as a second-line treatment in patients who have not had their spleen removed due to surgery being contraindicated.

ITP is a bleeding disorder caused by abnormally low levels of platelets in the blood. It is estimated there are around 3,000-3,500 cases in the UK.

Revolade increases platelet production through activation of the thrombopoietin receptor. By stimulating production, the drug helps to reduce bleeding.

“People living with ITP are at daily risk of bleeding and subsequent bruising, and this can have a detrimental effect on quality of life,” said Dr Carole Longson, Health Technology Evaluation Centre Director at NICE. “NICE is, therefore, pleased to be able to recommend eltrombopag for this condition.”

Final guidance is now expected to be published in May 2013.